Mooradian, Meghan J. http://orcid.org/0000-0002-8289-8015
Fintelmann, Florian J. http://orcid.org/0000-0002-0119-3903
LaSalle, Thomas J. http://orcid.org/0000-0002-8390-6072
Simon, Judit
Graur, Alexander http://orcid.org/0000-0001-8149-461X
Muzikansky, Alona
Mino-Kenudson, Mari
Shalhout, Sophia http://orcid.org/0000-0002-2783-5265
Kaufman, Howard L. http://orcid.org/0000-0003-1131-004X
Jenkins, Russell W. http://orcid.org/0000-0001-6110-2148
Lawrence, Donald
Lawless, Aleigha
Sharova, Tatyana
Uppot, Raul N.
Fang, Jacy http://orcid.org/0009-0006-6937-6868
Blaum, Emily M.
Gonye, Anna L. K. http://orcid.org/0000-0003-0034-1756
Gushterova, Irena
Boland, Genevieve M. http://orcid.org/0000-0002-7522-6173
Azzoli, Christopher
Hacohen, Nir http://orcid.org/0000-0002-2349-2656
Sade-Feldman, Moshe
Sullivan, Ryan J. http://orcid.org/0000-0001-5344-6645
Article History
Received: 25 November 2023
Accepted: 16 August 2024
First Online: 27 August 2024
Competing interests
: M.J.M. has served as a consultant/received honorarium from AstraZeneca, Immunai, Bristol Myers Squib, Xilio Therapeutics, Nektar Therapeutics, Catalyst Pharmaceuticals, Regeneron Pharmaceuticals. F.J.F. reports research support from Pfizer as well as consulting and speaking for Boston Scientific. T.J.L. has served as a consultant for Chemomab Therapeutics. M.M.K. has served as a consultant/received honorarium from AstraZeneca, Janssen Oncology, Pfizer, Innate, Repare, Sanofi, and Daiichi-Sankyo, and has received royalties from Elsevier. H.L.K. is an employee of Ankyra Therapeutics and has served on advisory boards for Castle Biosciences, MidaTech Pharma, Tatum Biosciences, and Virogin Biotech. R.W.J. is on the advisory board for XSphera Biosciences and has received research support from Monopteros Therapeutics and has served as a paid consultant/received honoraria from Incyte, G1 Therapeutics, and Bioxcel Therapeutics. R.N.U.: has served as paid consultant for Boston Scientific, German Accelerator. G.M.B. has sponsored research agreements through her institution with: Olink Proteomics, Teiko Bio, InterVenn Biosciences, Palleon Pharmaceuticals. She served on advisory boards for: Iovance, Merck, Nektar Therapeutics, Novartis, and Ankyra Therapeutics. She has served as a consultation for: Merck, InterVenn Biosciences, Iovance, and Ankyra Therapeutics. She holds equity in Ankyra Therapeutics. N.H. holds equity in and advises Danger Bio/Related Sciences, is on the scientific advisory board of Repertoire Immune Medicines and CytoReason, owns equity in BioNtech, and receives research funding from Bristol Myers Squibb and Calico Life Science. R.J.S. has served as a paid consultant/member of scientific advisory board from BMS, Eisai, Iovance, Merck, Novartis, OncoSec, Pfizer; and has received research funding from Merck. M.S.F. received funding from Calico Life Sciences, Bristol-Myers Squibb, Istari Oncology and served as a consultant for Galvanize Therapeutics. The remaining authors declare no competing interests.